Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

WPD Pharmaceuticals Inc. (C:WBIO)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for WBIO within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 02, 2021 07:30 ET
WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland
WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces that it will hold its Annual and Special General Meeting of Shareholders (AGSM) on September 29, 2021 in Vancouver, Canada...
Read full article
Jul 12, 2021 07:30 ET
WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that CNS Pharmaceuticals Inc. (“CNS”) (NASDAQ:CNSP), the company that licenses the drug candidate Berubicin to...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
24.39
10.38
Price to Book - most recent quarter
--
4.96
3.31
Price to Cash Flow per share - TTM
--
17.72
13.33
Price to Free Cash Flow per share - TTM
--
--
31.14
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 15, 2021826-10,713
Jul 31, 202111,539-27,251
Jul 15, 202138,79010,098
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

WPD Pharmaceuticals Inc, formerly Westcot Ventures Corp, is a Canada-based biotechnology research and development company. The Company focuses on oncology, research and development of medicinal products involving biological compounds and small molecules. The Company has approximately 10 drug candidates with five that are in clinical development stage and five in pre-clinical development. The Company's drug development focuses on melanoma, brain cancer, leukemia and pancreatic cancer. Its portfolio for brain cancer includes WPD101, Berubicin and WP1066. Its portfolio for pancreatic cancer includes WP1066 and WP1732. Its portfolio for other cancers include WPD103, WP1220 and Annamycin.

See business summary

 

Twitter

Search (past week) for $WBIO.CA

  • No tweets found